Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma

Abstract Background CD58 has been demonstrated to be abnormally expressed in multiple hematopoietic malignancies and solid tumors and plays an essential role in tumorigenesis and progression; however, its clinical significance and prognostic value in pancreatic ductal adenocarcinoma (PDAC) remain un...

Full description

Bibliographic Details
Main Authors: Yalu Zhang, Qiaofei Liu, Jingkai Liu, Quan Liao
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Cancer Cell International
Subjects:
Online Access:https://doi.org/10.1186/s12935-021-02037-0
id doaj-dcc1fc493d3341ebb126d2d9379ad860
record_format Article
spelling doaj-dcc1fc493d3341ebb126d2d9379ad8602021-07-04T11:48:28ZengBMCCancer Cell International1475-28672021-06-0121111510.1186/s12935-021-02037-0Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinomaYalu Zhang0Qiaofei Liu1Jingkai Liu2Quan Liao3Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical CollegeDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical CollegeDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical CollegeDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical CollegeAbstract Background CD58 has been demonstrated to be abnormally expressed in multiple hematopoietic malignancies and solid tumors and plays an essential role in tumorigenesis and progression; however, its clinical significance and prognostic value in pancreatic ductal adenocarcinoma (PDAC) remain unknown. Methods Based on diverse online public databases and 81 PDAC samples of tissue microarray-based immunohistochemistry (IHC), we evaluated CD58 expression in PDAC patients and analyzed its association with clinicopathological characteristics, clinical outcomes, and infiltration of immune cells in PDAC. Furthermore, the correlation between CD58 and the cancer stem cell (CSC)-related, epithelial–mesenchymal transition (EMT)-related, and immune-related markers were detected. Besides, the functional enrichment analysis and related pathways were analyzed and visualized. Results CD58 expression was elevated in pancreatitis and PDAC tissues than normal pancreas or adjacent nontumor tissues. The positive cases of CD58 (e.g. more than 50% positive cells) in PDAC account for 95.06% (77/81). Upregulated CD58 in cancer tissues was associated with worse histological grade, larger tumor size, and poorer overall survival and disease-free survival in PDAC patients. Furthermore, Cox multivariate regression analysis revealed that CD58 was an independent prognostic factor in PDAC. CD58 expression was correlated with infiltrations of neutrophils, CD8+ T cells, and dendritic cells (DCs). In addition, correlation gene analysis indicated that CD58 expression was strongly correlated with immune-related, EMT-related, and CSC-related markers. Functional enrichment analysis and KEGG pathway manifested that CD58 might be involved in PDAC initiation and progression. Conclusions CD58 expression is upregulated in PDAC tissues and its high expression is notably related to poor survival of PDAC. Therefore, CD58 may serve as a novel and effective marker for predicting the prognosis of PDAC patients.https://doi.org/10.1186/s12935-021-02037-0CD58Pancreatic ductal adenocarcinomaSurvivalPrognosisImmune infiltration
collection DOAJ
language English
format Article
sources DOAJ
author Yalu Zhang
Qiaofei Liu
Jingkai Liu
Quan Liao
spellingShingle Yalu Zhang
Qiaofei Liu
Jingkai Liu
Quan Liao
Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
Cancer Cell International
CD58
Pancreatic ductal adenocarcinoma
Survival
Prognosis
Immune infiltration
author_facet Yalu Zhang
Qiaofei Liu
Jingkai Liu
Quan Liao
author_sort Yalu Zhang
title Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
title_short Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
title_full Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
title_fullStr Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
title_full_unstemmed Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
title_sort upregulated cd58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
publisher BMC
series Cancer Cell International
issn 1475-2867
publishDate 2021-06-01
description Abstract Background CD58 has been demonstrated to be abnormally expressed in multiple hematopoietic malignancies and solid tumors and plays an essential role in tumorigenesis and progression; however, its clinical significance and prognostic value in pancreatic ductal adenocarcinoma (PDAC) remain unknown. Methods Based on diverse online public databases and 81 PDAC samples of tissue microarray-based immunohistochemistry (IHC), we evaluated CD58 expression in PDAC patients and analyzed its association with clinicopathological characteristics, clinical outcomes, and infiltration of immune cells in PDAC. Furthermore, the correlation between CD58 and the cancer stem cell (CSC)-related, epithelial–mesenchymal transition (EMT)-related, and immune-related markers were detected. Besides, the functional enrichment analysis and related pathways were analyzed and visualized. Results CD58 expression was elevated in pancreatitis and PDAC tissues than normal pancreas or adjacent nontumor tissues. The positive cases of CD58 (e.g. more than 50% positive cells) in PDAC account for 95.06% (77/81). Upregulated CD58 in cancer tissues was associated with worse histological grade, larger tumor size, and poorer overall survival and disease-free survival in PDAC patients. Furthermore, Cox multivariate regression analysis revealed that CD58 was an independent prognostic factor in PDAC. CD58 expression was correlated with infiltrations of neutrophils, CD8+ T cells, and dendritic cells (DCs). In addition, correlation gene analysis indicated that CD58 expression was strongly correlated with immune-related, EMT-related, and CSC-related markers. Functional enrichment analysis and KEGG pathway manifested that CD58 might be involved in PDAC initiation and progression. Conclusions CD58 expression is upregulated in PDAC tissues and its high expression is notably related to poor survival of PDAC. Therefore, CD58 may serve as a novel and effective marker for predicting the prognosis of PDAC patients.
topic CD58
Pancreatic ductal adenocarcinoma
Survival
Prognosis
Immune infiltration
url https://doi.org/10.1186/s12935-021-02037-0
work_keys_str_mv AT yaluzhang upregulatedcd58isassociatedwithclinicopathologicalcharacteristicsandpoorprognosisofpatientswithpancreaticductaladenocarcinoma
AT qiaofeiliu upregulatedcd58isassociatedwithclinicopathologicalcharacteristicsandpoorprognosisofpatientswithpancreaticductaladenocarcinoma
AT jingkailiu upregulatedcd58isassociatedwithclinicopathologicalcharacteristicsandpoorprognosisofpatientswithpancreaticductaladenocarcinoma
AT quanliao upregulatedcd58isassociatedwithclinicopathologicalcharacteristicsandpoorprognosisofpatientswithpancreaticductaladenocarcinoma
_version_ 1721319892050771968